

JOHNSON

PHARMACARE LIMITED

CIN: L51100GJ1994PLC022388



Registered Office Address - Regus Business Centre, Privilon,
East Wing, 2nd Floor, Sarkhej Gandhinagar Highway, Bodakdev,
Ahmedabad - 380054

E-Mail:sunandshineworldwidelt@gmail.com

Date: 14.11.2025

To,
Listing Department,
BSE Limited
P J Tower, Dalal Street
Mumbai-400001

Scrip Code: 532154

Security ID: JOHNPBARMA

Sub: Outcome of the Board Meeting of the board held on 14th November 2025.

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Friday 14th November, 2025 at the Registered Office of the Company and transacted the following major businesses:

1) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September, 2025.

The board meeting commented at 07:45 PM and concluded at 08:15 PM

Please take the above intimation in your records.

Thanking You.

Yours Faithfully,
For, Johnson Pharmicare Limited

Umesh Kumar
Chairperson
DINo.: 07015921

Johnson Pharmacare Limited

CIN:- L51100GJ1994PLC022388

Regd. Office: Regus, 1101-1106, Earth Arise, 11th Floor, Sarkhej Gandhinagar Highway, Makarba, Ahmedabad - 380015

Email:- sunandshineworldwidetd@gmail.com

Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2025

Sl no.	Particulars	Quarter Ended			Six Months Ended		(Rs. In lacs)
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	Year Ended 31 Mar 2025
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME						
(a)	Revenue From Operation	-	-	-	-	-	-
(b)	Other Income	-	-	-	-	-	(33.34)
	Total Income from Operations (Net)	-	-	-	-	-	(33.34)
2	EXPENSES						
(a)	Cost of material consumed	-	-	-	-	-	-
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(c)	Employee benefit expense	0.30	0.30	-	0.60	-	0.90
(d)	Finance Costs	-	-	-	-	-	-
(e)	Depreciation and amortization expense	-	-	-	-	-	-
(f)	Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	0.04	5.04	0.08	5.08	4.07	6.98
	Total Expenses	0.34	5.34	0.08	5.68	4.07	7.88
3	Profit / (Loss) from operations before exceptional items Tax (1-2)	(0.34)	(5.34)	(0.08)	(5.68)	(4.07)	(41.22)
4	Exceptional Items	-	-	-	-	-	(17.16)
5	Profit / (Loss) before Tax (3 ± 4)	(0.34)	(5.34)	(0.08)	(5.68)	(4.07)	(58.38)
6	Tax Expense	-	-	-	-	-	-
7	Net Profit / (Loss) after Tax (5 - 6)	(0.34)	(5.34)	(0.08)	(5.68)	(4.07)	(58.38)
8	Other Comprehensive Income (net of tax)	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7 ± 8)	(0.34)	(5.34)	(0.08)	(5.68)	(4.07)	(58.38)
10	Paid-up equity share capital (Face Value of Rs.1/- each)	5,500.00	5,500.00	5,500.00	5,500.00	5,500.00	5,500.00
11	Other Equity	-	-	-	-	-	116.91
12	Earnings Per Share (of Rs. 1/- each) (not annualised):						
(a)	Basic	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.01)
(b)	Diluted	(0.00)	(0.00)	(0.00)	(0.00)	(0.00)	(0.01)

Johnson Pharmacare Limited

CIN:- L51100GJ1994PLC022388

Regd. Office: Regus, 1101-1106, Earth Arise, 11th Floor, Sarkhej Gandhinagar Highway, Makarba, Ahmedabad - 380015

Email:- sunandshineworldwidetd@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 30th September, 2025	As at 31st March, 2025
Particulars		Un-Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	-	-
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	Financial assets		
	Investments	4,229.16	4,229.16
	Loans	-	-
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	-	-
	Sub-total - Non-Current Assets	4,229.16	4,229.16
2	Current assets		
	Inventories	-	-
	Financial assets		
	Investments	-	-
	Trade receivables	-	-
	Cash and cash equivalents	3.11	1.43
	Bank balances other than Cash and Cash equivalents above	-	-
	Loans, Current	1,469.50	1,427.00
	Other financial assets	-	-
	Other current assets	135.00	135.00
	Assets classified as held for sale	-	-
	Sub-total - Current Assets	1,607.61	1,563.43
	TOTAL - ASSETS	5,836.76	5,792.59
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share capital	5,500.00	5,500.00
	Other equity	111.24	116.91
	Sub-total - Shareholders' funds	5,611.24	5,616.91
2	LIABILITIES		
	Non-current liabilities		
	Financial liabilities		
	Borrowings, non-Current	110.54	60.54
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	Sub-total - Non-current liabilities	110.54	60.54
3	Current liabilities		
	Financial liabilities		
	Borrowings, Current	-	-
	Trade payables, Current	-	-
	Other financial liabilities	-	-
	Other current liabilities	114.98	115.13
	Provisions	-	-
	Current tax liabilities (net)	-	-
	Sub-total - Current liabilities	114.98	115.13
	TOTAL - EQUITY AND LIABILITIES	5,836.76	5,792.59

Johnson Pharmacare Limited

CIN:- L51100GJ1994PLC022388

Regd. Office: Regus, 1101-1106, Earth Arise, 11th Floor, Sarkhej Gandhinagar Highway, Makarba, Ahmedabad - 380015

Email:- sunandshineworldwidetd@gmail.com

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 13, 2025
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board
For, Johnson Pharmacare Limited

Place : Ahmedabad
Date : 14th November, 2025

Umesh Kumar
Wholetime Director

Johnson Pharmacare Limited

CIN:- L51100GJ1994PLC022388

Regd. Office: Regus, 1101-1106, Earth Arise, 11th Floor, Sarkhej Gandhinagar Highway, Makarba, Ahmedabad - 380015

STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2025

(Rs. in Lakhs, unless otherwise stated)

Particulars	30.09.2025	30.09.2024
	Rupees	Rupees
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax	- 5.68	- 4.07
Adjustment For :		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/amortization on continuing operation	-	-
Interest expenses	-	-
Operating profit before working capital changes	- 5.68	- 4.07
Movement in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	-	-
Increase/(decrease) in Short Term Loan & Advances	- 42.50	-
Increase/(decrease) in Current Liabilities	- 0.15	0.16
Increase/(decrease) in Trade Payable	-	-
Increase/(decrease) in Other Current Assets	-	-
Direct taxes paid (net of refunds)	-	-
Net Cash Flow from Operating Activities(A)	- 48.33	- 3.91
B. CASH FLOW FROM INVESTING ACTIVITIES		
Investments /withdrawal in Partnership Firm	-	-
Purchase / Sale of Fixed Assets	-	-
Increase/(decrease) in Long Term Loan & Advances	-	-
Net Cash Flow from Investing Activities(B)	-	-
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceed (Repayment) from long term borrowing	50.00	3.83
Proceed (Repayment) from short term borrowing	-	-
Proceed from Preferential Warrants	-	-
Net Cash Flow from Financing Activities(C)	50.00	3.83
Net increase/(decrease) in cash & cash equivalents(A+B+C)	1.67	- 0.08
Cash and Cash equivalents (Opening Balance)	1.44	0.14
Cash and Cash equivalents (Closing Balance)	3.11	0.06

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date
For, Rishi Sekhri and Associates,
Chartered Accountants
FRN: 128216w

SD/-
CA Rishi Sekhri
Partner
M.NO. 126656

Place: Mumbai
Date : 14th November, 2025

For and on Behalf of the Board
For, Johnson Pharmacare Limited

Umesh Kumar
Chairperson

Place: Ahmedabad
Date : 14th November, 2025



RISHI SEKHRI AND ASSOCIATES CHARTERED ACCOUNTANTS


GROUND FLOOR, BANDRA ARCADE BUILDING, OPP. RAILWAY STATION, BANDRA (WEST), MUMBAI - 400 050.
Tel.: 9820501848, Email : rishisekhri@gmail.com

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report To
The Board of Directors
Johnson Pharmacare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Johnson Pharmacare Limited** (the "Company") for the quarter ended September 30, 2025 and year to date from April 01, 2025 to September 30, 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Rishi Sekhri and Associates
Chartered Accountants
FRN: 128216W


CA Rishi Sekhri
Partner
NO. 126656
PLACE: Mumbai
Date: 14/11/2025
UDIN: 25126656NKTCKV4151

